CompaniesArrys Therapeutics

Arrys Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (2)
View all

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

72

By Phase

PHASE1/PHASE2: 1PHASE1: 1

By Status

TERMINATED: 1COMPLETED: 1

Recent Trials

NCT03696212Lead Sponsor
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
PHASE1/PHASE2Terminated
18 participants
Started: Jan 8, 2019 · Completed: Feb 15, 2021
NCT03658772Lead Sponsor
Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
PHASE1Completed
54 participants
Started: Sep 20, 2018 · Completed: Mar 7, 2023
Related Companies
Kyn Therapeutics----------------------------------------if You Believe Any Of This Information Is Incorrect
subsidiary